| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/23/2006 | US20060040933 Antiinflammatory agents |
| 02/23/2006 | US20060040931 Benzomorpholine derivatives |
| 02/23/2006 | US20060040912 Compounds for pdt |
| 02/23/2006 | US20060040876 Modulation of peroxisome proliferator-activated receptors |
| 02/23/2006 | US20060040853 Methods and compositions useful for modulation of angiogenesis using protein kinase Raf and Ras |
| 02/23/2006 | US20060040851 Gag-peptide complex |
| 02/23/2006 | US20060040371 Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy |
| 02/23/2006 | US20060040360 Adipocyte complement related protein homolog zacrp7 |
| 02/23/2006 | US20060040331 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents |
| 02/23/2006 | US20060040312 Uses of kappa-conotoxin PVIIA |
| 02/23/2006 | US20060040266 Diagnostics and therapeutics for diseases associated with neuromedin u2 receptor (nmu2) |
| 02/23/2006 | US20060040265 Regulation of novel human asparagine-hydroxylases |
| 02/23/2006 | US20060039937 Composition having antioxidant properties |
| 02/23/2006 | US20060039903 Immunomodulation and effect on cell processes relating to serotonin family receptors |
| 02/23/2006 | DE20023745U1 Method of modulating expression of an endogenous cellular gene in a cell to prevent gene activation or prevent repression of gene expression comprising contacting a target sequence with a zinc finger protein |
| 02/23/2006 | DE102004039065A1 New N-substituted 1-benzyl-1H-(1,2,3)-triazole-4-carboxamides, are dopamine and alpha-1 adrenergic receptor ligands useful for treating diseases of the urinary tract, vascular system or CNS |
| 02/23/2006 | DE102004013294A1 Use of tropisetron and/or 5-hydroxy tryptophan-3-receptor-antagonist to reduce apoplectic condition in an infarct area by blocking serotonin-3-receptor, down-regulate inflammation process and strengthen the serotonin receptor expression |
| 02/23/2006 | CA2575563A1 Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors |
| 02/23/2006 | CA2573974A1 Tgf-.beta. gene expression inhibitor |
| 02/23/2006 | CA2573761A1 Use of estrogen related receptor-modulating aryl ethers |
| 02/23/2006 | CA2573720A1 Netrin-related compositions and uses |
| 02/22/2006 | EP1627876A1 Heterocyclic condensed compounds useful as antidiuretic agents |
| 02/22/2006 | EP1627875A1 Method for producing cyclic diamine derivative or salt thereof |
| 02/22/2006 | EP1627866A1 Carboxylic acid compound and medicine containing the same |
| 02/22/2006 | EP1627638A1 Fortifier |
| 02/22/2006 | EP1627636A1 Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| 02/22/2006 | EP1627633A1 Oral pharmaceutical forms of administration with a delayed action with tramadol |
| 02/22/2006 | EP1626736A1 C1 inhibitor with short half-life for transient treatment |
| 02/22/2006 | EP1626728A2 Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders |
| 02/22/2006 | EP1626726A2 Use of lornoxicam or lornoxicam analogue compounds |
| 02/22/2006 | EP1626724A2 Method and kit for regulation of microvascular tone |
| 02/22/2006 | EP1626718A2 Methods of treating ischemic related conditions |
| 02/22/2006 | EP1626714A2 Diaryl ureas for diseases mediated by pdgfr |
| 02/22/2006 | EP1490029A4 Controlled release drug delivery system of pravastatin |
| 02/22/2006 | EP1456210B1 Pyrazolyl-substituted triazoloquinoxalines |
| 02/22/2006 | EP1406622B1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 02/22/2006 | EP1385856B1 Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
| 02/22/2006 | EP1385839B1 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists |
| 02/22/2006 | EP1384472B1 Method for producing an organic solvent-free lycopene concentrate, the resulting concentrate and composition comprising said concentrate |
| 02/22/2006 | EP1237874B1 Selective neurokinin antagonists |
| 02/22/2006 | EP1224187B1 Certain alkylene diamine-substituted heterocycles |
| 02/22/2006 | EP1194584B1 Method for producing oligopolysaccharides |
| 02/22/2006 | EP1121156B1 Polymer conjugates of interferon beta- 1a and their uses |
| 02/22/2006 | EP0766580B1 Compositions of prostacyclin, pge or a nitrovasodilator or combinations thereof for the treatment of diseases of the vascular system |
| 02/22/2006 | CN1738830A 培哚普利 Perindopril |
| 02/22/2006 | CN1738827A Novel ampiphilic derivatives of alpha-c-phenyl n-tert-butyl nitrone |
| 02/22/2006 | CN1738817A Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same. |
| 02/22/2006 | CN1738806A Oxo-azabicyclic compounds |
| 02/22/2006 | CN1738795A Indenoncarboxylic acids derivatives and their use for the treatment of and preventing diabetes and dyslipidaemia |
| 02/22/2006 | CN1738788A Substituted phenyl naphthalenes as estrogenic agents |
| 02/22/2006 | CN1738665A Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases |
| 02/22/2006 | CN1738638A Medicinal composition for treating ischemic cardiac failure |
| 02/22/2006 | CN1738632A Bioavailability enhancing activity of carum carvi extracts and fractions thereof |
| 02/22/2006 | CN1738624A Method of treatment of myocardial infarction |
| 02/22/2006 | CN1738618A Pharmaceutical compositions and their uses |
| 02/22/2006 | CN1738617A Pharmaceutical compositions for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases |
| 02/22/2006 | CN1738599A Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| 02/22/2006 | CN1738548A Compositions containing coenzyme q10 |
| 02/22/2006 | CN1737103A Propolis wine |
| 02/22/2006 | CN1737007A Gastrodine derivative, its preparation method, pharmaceutical composition and uses |
| 02/22/2006 | CN1736475A Troxerutin brain protein hydrolysate for injection and preparation process thereof |
| 02/22/2006 | CN1736469A Chinese medicine for treating apoplexy sequelae and preparation process thereof |
| 02/22/2006 | CN1736465A Apparatus and method for manufacturing tabasheer |
| 02/22/2006 | CN1736464A Medicine for treating hemiparalysis |
| 02/22/2006 | CN1736462A Chinese proprietary medicine making fleece-flower root as main raw material |
| 02/22/2006 | CN1736429A Blood stasis dispelling dripping pills for treating coronary heart disease, angina pectoris and hyperlipemia and preparation process thereof |
| 02/22/2006 | CN1736426A Chinese medicinal composition adapted for therapeutic needs of acute period or precursor period of apoplexy |
| 02/22/2006 | CN1736425A Chinese medicinal capsule for treating piles and its preparing process |
| 02/22/2006 | CN1736422A Composition of Chinese medicine effective ingredients for treating cardiovascular disease |
| 02/22/2006 | CN1736416A Compound medicine for treating coronary heart disease and angina pectoris and its preparing process |
| 02/22/2006 | CN1736413A Finely prepared sustained-releasing formulation for coronary disease and preparation process thereof |
| 02/22/2006 | CN1736412A Orally administered composition containing fat soluble ingredient of red sage root |
| 02/22/2006 | CN1736392A Injection with adetphos and magnesium chloride and preparation process thereof |
| 02/22/2006 | CN1736384A Mixture of higher primary aliphatic alcohols with acetylsalicylic acid and pharmaceutical formulation |
| 02/22/2006 | CN1736376A Modulation of peroxisome proliferator-activated receptors |
| 02/22/2006 | CN1736373A Application of D-serine in preparation of medicine or drink for preventing or treating cerebral ischemia/anoxia caused brain injury |
| 02/22/2006 | CN1736262A Composition containing flavonoid, jphosphatidyl inositol and/or inosite |
| 02/22/2006 | CN1243093C Using phenylethyl caffeiate derivative, capsaicin and resin toxin to inhibit NF-KB |
| 02/22/2006 | CN1243018C Blood vessel generating inhibitor |
| 02/22/2006 | CN1242992C Cyclic diamine compounds bearing six-membered cyclic groups |
| 02/22/2006 | CN1242809C Applications of T-BAM (CD40L) technology in preparation of medicine to treat diseases involving smooth muscle cell |
| 02/22/2006 | CN1242808C Chinese medicine for treating pulmonary heart disease |
| 02/22/2006 | CN1242803C Small honey pills for treating thrombus disease and its preparing process |
| 02/22/2006 | CN1242801C Medicinal composition for treating coronary heart disease and angina pectoris |
| 02/22/2006 | CN1242789C Process for preparing Chinese medicine soft capsule for treating and preventing thrombotic obliterating disease |
| 02/22/2006 | CN1242786C Process for preparing Chinese medicinal dripping pills for treating and preventing ischemic cardio-cerebral vascular diseases |
| 02/22/2006 | CN1242782C Medicine for treating cerebral thrombus and its preparing process |
| 02/22/2006 | CN1242778C Medicine for treating cardiovascular and cerebrovascular disease and hemiparalysis |
| 02/22/2006 | CN1242772C Chinese medicine for hemorrhoid |
| 02/22/2006 | CN1242766C Medicine for preventing and treating chronic exhaustion syndrome and preparing method thereof |
| 02/22/2006 | CN1242746C Medicine compound contg. troxeration |
| 02/22/2006 | CN1242741C Preparation and diabetic use of gibberellins |
| 02/21/2006 | US7002018 Process for the preparation of amorphous form of torsemide |
| 02/21/2006 | US7001920 Psychological disorders; antidepressant |
| 02/21/2006 | US7001919 Crystallization from solvent system |
| 02/21/2006 | US7001917 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents |
| 02/21/2006 | US7001914 Compounds |
| 02/21/2006 | US7001910 substituted pyrimidinyl-amino-ethoxy benzyl-thiazolidine-diones; hypoglycemic agents |
| 02/21/2006 | US7001909 For therapy of cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease |
| 02/21/2006 | US7001908 Arylpiperazines having activity at the serotonin 1A receptor |